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Abstract 
Background: Hepatitis B virus (HBV) infection is an important cause of morbidity and mortality with a very high bur-
den in Africa. The risk of developing chronic infection is marked if the infection is acquired perinatally, which is largely 
preventable through a birth dose of HBV vaccine. We examined the cost-effectiveness of a birth dose of HBV vaccine 
in a medical setting in Ethiopia.
Methods: We constructed a decision analytic model with a Markov process to estimate the costs and effects of a 
birth dose of HBV vaccine (the intervention), compared with current practices in Ethiopia. Current practice is pen-
tavalent vaccination (DPT-HiB-HepB) administered at 6, 10 and 14 weeks after birth. We used disability-adjusted life 
years (DALYs) averted to quantify the health benefits while the costs of the intervention were expressed in 2018 USD. 
Analyses were based on Ethiopian epidemiological, demographic and cost data when available; otherwise we used a 
thorough literature review, in particular for assigning transition probabilities.
Results: In Ethiopia, where the prevalence of HBV among pregnant women is 5%, adding a birth dose of HBV vac-
cine would present an incremental cost-effectiveness ratio (ICER) of USD 110 per DALY averted. The estimated ICER 
compares very favorably with a willingness-to-pay level of 0.31 times gross domestic product per capita (about USD 
240 in 2018) in Ethiopia. Our ICER estimates were robust over a wide range of epidemiologic, vaccine effectiveness, 
vaccine coverage and cost parameter inputs.
Conclusions: Based on our cost-effectiveness findings, introducing a birth dose of HBV vaccine in Ethiopia would 
likely be highly cost-effective. Such evidence could help guide policymakers in considering including HBV vaccine 
into Ethiopia’s essential health services package.
Keywords: Hepatitis B virus, Vaccines, Mother-to-child transmission, Birth dose of HBV vaccine, Cost-effectiveness 
analysis, Sub-Saharan Africa, Ethiopia
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Background
Hepatitis B virus (HBV) infection remains an impor-
tant cause of morbidity and mortality globally. Accord-
ing to 2015 estimates by the World Health Organization 
(WHO), about 260 million individuals (3.5% of the 
world’s population) were living with chronic HBV 
infection in the world [1]. Most HBV infections (68%) 
occurred in the African and Western Pacific regions 
where the HBV prevalence was the highest (6.1% in the 
African region and 6.2% in Western Pacific among the 
general population, respectively) [1]. In 2015, viral hepa-
titis led to 1.34 million deaths globally, of which 66% were 
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resulting from complications of chronic HBV infection 
such as cirrhosis (53%) and hepatocellular carcinoma 
(34%) [1].
The prevalence of HBV infection is estimated at 7.4% 
among the general population of Ethiopia, which is at 
the highest end of intermediate endemicity1 [2]. Like-
wise, according to a meta-analysis of prevalence stud-
ies in Ethiopia, the prevalence of HBV infection among 
pregnant women was estimated at 4.7% that is lower 
than estimates from other African countries such as 
Nigeria, Cameroon and Ghana where the prevalence of 
HBV infection among pregnant women ranged from 9.8 
to 14.1% [3]. Pregnant women infected with HBV can 
potentially transmit the virus to their infants usually 
during birth. The risk of transmission to the newborn is 
largely dependent on the presence or absence of the hep-
atitis B virus envelope antigen (HBeAg) in HBV-infected 
pregnant women. In Africa, infants born to mothers who 
are positive for both hepatitis B surface antigen (HBsAg) 
and HBeAg carry a 28% risk of transmission with a lower 
risk (8%) in mothers who have lost HBeAg [4]. A study 
on the risk of mother to child transmission (MTCT) of 
HBV in Ethiopia has shown a higher transmission rate 
[5]. Perinatally infected infants are at the highest risk of 
chronic HBV infection that occurs in 80–90% of infected 
infants [6].
Measures to control viral hepatitis have progressively 
increased globally [1]. Most countries including Ethio-
pia have introduced hepatitis B vaccine into their routine 
infant immunization programs. The birth dose of hepa-
titis B (HepB-BD) vaccine is the main modality in the 
prevention of mother to child HBV transmission. Ide-
ally, the birth dose should be given within 24 h of birth 
but can still be partially effective even if given beyond, 
its effectiveness diminishing with the passage of time 
[7]. Unfortunately, as of 2015, only 10% of African coun-
tries had introduced HepB-BD vaccine, and it is not yet 
introduced in Ethiopia [1]. Furthermore, other preventive 
measures such as hepatitis B immunoglobulin or medica-
tions for the treatment of HBV infection are not yet part 
of Ethiopia’s essential health service package [8]. In the 
absence of universal HepB-BD vaccine or other effective 
interventions, perinatally acquired HB infection remains 
a major cause of chronic liver disease when infected chil-
dren reach adulthood [9].
The fight against viral hepatitis is gathering momentum 
globally. Combating hepatitis is included in the Sustaina-
ble Development Goals (SDG 3.3) [10]. The World Health 
Assembly in 2016 adopted a Global Health Sector Strat-
egy on viral hepatitis with elimination as its overarching 
goal [1]. In line with the global response, Ethiopia’s Fed-
eral Ministry of Health (FMoH) has developed guidelines 
aiming at scaling up viral hepatitis preventive measures, 
and standardized screening and management of patients 
with viral hepatitis toward improved outcome [11].
Evidence on the cost-effectiveness of HepB-BD vaccine 
is scarce in sub-Saharan Africa. A cost-effectiveness anal-
ysis (CEA) of adding HepB-BD vaccine in Mozambique 
has shown that it could be highly cost-effective within 
the Mozambique health system [12]. Yet, CEA results 
may vary with the setting, the epidemiology of HBV and 
intervention costs. Therefore, in this paper, we evaluate 
the incremental cost-effectiveness of adding HepB-BD 
vaccine to the three-dose regimen given to infants at 
6, 10 and 14  weeks after birth. The evidence we gener-
ate serve as a useful input for Ethiopian policymakers in 
considering including HepB-BD vaccine into the national 
essential health services package.
Methods
We constructed a decision analytic model with a Markov 
process (Additional file  1 and Fig.  1) to estimate inter-
vention costs and health impact of an infected individual 
over a lifetime. We used TreeAge Pro 2018 software for 
the analysis. As demonstrated in the Additional file  1 
and Fig. 1, the model reflects the natural history of peri-
natally acquired HBV-infection [13]. We compared two 
strategies. In the novel strategy (HepB-BD vaccine-
plus) all infants receive HepB-BD vaccine (monovalent) 
within 24 h of delivery and continue on with the penta-
valent vaccine (DPT-HiB-HepB) series starting at the age 
of 6  weeks. We assumed 50% of the target birth cohort 
will be born in health care facilities and receive the birth 
dose in a medical setting; following the latest skilled birth 
attendance rate in Ethiopia [14]. We further assumed 
that the government rolls-out HepB-BD vaccine to the 
whole birth cohort and therefore incur costs but vaccine 
effectiveness would vary depending on the skilled birth 
attendance rate in Ethiopia. In the current strategy, the 
birth cohort will only receive the existing pentavalent 
vaccination schedule at 6, 10 and 14 weeks after birth.
In the model, we assumed HepB-BD vaccine would 
prevent against MTCT of HBV infection during birth/
delivery (vertical transmission), otherwise the two strate-
gies would have similar efficacy on infections that occur 
later in life (horizontal transmissions). We used data on 
HBV prevalence among pregnant women, vaccine effec-
tiveness, and the risk of perinatal transmission to calcu-
late the percentage of children born with HBV infection. 
Infected infants either develop acute symptomatic 
infection with a risk of fulminant hepatitis or remain 
1 The endemicity of hepatitis B virus is determined by the prevalence of 
HBsAg in the general population of a defined geographic area: prevalence of 
HBsAg > 8% is high endemicity, 2–7% intermediate endemicity, and HBsAg 
prevalence < 2% is low endemicity [6].
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asymptomatic (Additional file  1). Even though sympto-
matic acute infections occur less frequently in infants, we 
accounted for their costs and health consequences in our 
model (see Additional file 1) [15, 16]. Perinatally infected 
infants develop acute symptomatic infections early in 
life, therefore we calculated disability-adjusted life years 
(DALYs)2 (based on life expectancy at birth adjusted for 
health state valuations from WHO-CHOICE) for only 
fatal cases and did not account for the lost quality of 
life for the duration of acute illness [17, 18]. The major-
ity (90%) of the asymptomatic cases and about 33% of 
those surviving fulminant hepatitis will develop chronic 
HBV infection [4, 15]. Most perinatally infected individu-
als enter the immunoactive phase and develop HBeAg 
positive chronic hepatitis with elevated liver enzyme 
(alanine aminotransferase) levels only after 10–30  years 
of infection [19]. Therefore, we started the Markov pro-
cess at age 20 years. Individuals with chronic HBV infec-
tion are simulated within the Markov process either 
as an inactive carrier or with chronic active hepatitis 
(CAH). Individuals who do not require antiviral therapy 
are considered inactive carriers and CAH are those who 
fulfill the treatment criteria (irrespective of the HBeAg 
status). A study in Ethiopia has evaluated treatment eli-
gibility and response to antiviral management of chronic 
hepatitis B infection [20]. In this study, among indi-
viduals 18–25  years of age with chronic HBV infection, 
nearly a quarter of patients (25%) were eligible to anti-
viral treatment (ALT > 80  U/L and viral load > 2000  IU/
mL). Therefore, in our model 75% of the individuals 
with chronic HBV infection began the Markov process 
as inactive carriers while 25% as CAH. Even though 
there are studies that document clearance of HBsAg (in 
6–17% of the cases) in Caucasian children who acquired 
chronic HBV infection horizontally, such data for perina-
tally infected children in sub-Saharan Africa were lacking 
where there is limited access to antiviral treatment [21, 
22]. Therefore, our model did not account for state tran-
sitions from either inactive carriers or CAH to HBsAg 
clearance (no infection).
We ran the Markov process for 51 cycles, which cor-
responds to the average life expectancy of both males and 
females at age 20  years in Ethiopia [17]. Every Markov 
cycle lasts 1  year allowing infected individuals to pass 
through different morbid states based on their transition 
probabilities. In each annual cycle, infected individuals 
could incur costs related to medical care and health out-
comes depending on their health state. Subsequently for 
each strategy, the costs and effects accrued in each of the 
decision trees and the Markov cycles are added and com-
pared to calculate the incremental cost-effectiveness ratio 
(ICER).
Epidemiologic, probability and effectiveness data
The overall prevalence of HBsAg among pregnant 
women in Ethiopia was estimated at 4.7% [3]. The 
risk of perinatal transmission varies by the maternal 
HBeAg status, where HBeAg-positive mothers carry a 
higher risk of transmission [4]. Prevalence of HBeAg 
among HBsAg-positive pregnant women in Ethiopia is 
unknown; therefore we used the mean prevalence from 
several sub-Saharan African countries [4]. Table 1 sum-
marizes epidemiologic and probability data inputs used 














Fig. 1 Markov process showing the different health states
2 Most of the deaths from perinatally acquired acute fulminant hepatitis occur 
during infancy. Using a life table for Ethiopia, adjusted for health state valu-
ations, we computed the DALYs lost associated with each death (54.3 years). 
This value was used in the model to quantify the DALYs lost associated with 
deaths due to fulminant hepatitis.
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a spectrum of disease conditions with different probabili-
ties (see Fig. 1 and Additional file 1). Local data on transi-
tion probabilities among different health states were not 
available. Therefore we used data from settings that are 
similar to the Ethiopian context when available (Table 1) 
[23, 24]. Similar to what has been used in acute symp-
tomatic infections, DALYs averted were the measure of 
effectiveness for chronic HBV states, inline with WHO 
recommendations since chronic HBV infection results 
in both premature mortality and morbidity [23, 25]. 
Evidence on disability weights for the different disease 
states were gathered from the Global Burden of Diseases 
(GBD) study database but other sources were also sought 
when such data were not available in the GBD database 
(Table 2) [24, 26].
Vaccine effectiveness data based on a randomized con-
trolled trial (RCT) were not available locally and from 
other comparable sub-Saharan African countries. There-
fore we used data from other settings that were based on 
a systematic review of the efficacy of hepatitis B immu-
nization for newborn infants of HBsAg-positive moth-
ers where the protective efficacy of the vaccine was 72% 
(95% CI 60 to 80%) in preventing perinatal HBV trans-
mission [27]. Vaccine adverse effects that are usually mild 
were not factored into the model [6]. Deaths due to other 
causes (background mortality) were integrated in the 
Table 1 Epidemiologic parameters and annual transition probabilities used in the model
a In our model, patients with chronic active hepatitis (CAH) are eligible for antiviral treatment therefore we used transition probabilities of treated patients
b The highest vaccine utilization rate was based on administrative report for facility delivery in Ethiopia
Parameter Base assumptions Range for sensitivity 
analysis
Source
Prevalence of HBsAg among pregnant women 0.047 0.025–0.1 [3]
Prevalence of HBeAg among HBsAg positive mothers 0.116 0.05–0.25 [4]
Risk of perinatal transmission (HBeAg +) 0.279 0.1–0.6 [4]
Risk of perinatal transmission (HBeAg−) 0.08 0.02–0.29 [4]
Acute symptomatic cases (for children of HBeAg + mothers) 0.01 – [4]
Acute symptomatic cases (for children of HBeAg − mothers) 0.05 – [23]
Fulminant infections among symptomatic cases 0.001 – [15]
Risk of infant death from fulminant infection 0.7 – [15]
Risk of infant chronic infection among survivors of fulminant infection 0.33 – [15]
Risk of chronic HBV infection after perinatal infection 0.9 – [4]
Chronic HBV infected individuals requiring antiviral treatment (CAH) 0.25 – [20]
Inactive carriers among individuals with chronic HBV infection 0.75 – [20]
Annual transition probabilities and disease related mortality
 Inactive carrier to
  CAH 0.03 – [23]
  Compensated cirrhosis 0.007 – [24]
  HCC 0.0006 – [24]
 CAH  toa [24]
  Inactive carrier 0.55 0.3–0.7 [24]
  Compensated cirrhosis 0.0024 0.0012–0.0036 [24]
  HCC 0.003 0.002–0.007 [24]
 Compensated cirrhosis to
  Decompensated cirrhosis 0.035 – [23]
  HCC 0.033 – [23]
  Regression 0.24 – [24]
 Decompensated cirrhosis to
  Disease specific death 0.28 – [23]
  HCC 0.15 – [23]
 HCC to
  Disease specific death 0.29 – [23]
Vaccine effectiveness 0.72 0.6–0.8 [27]
Vaccine utilization 0.5 0.1–0.66b [14]
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model using the World Health Organization’s life tables 
for Ethiopia [17].
Costs
Costs were estimated from a health provider perspective 
and only included direct medical costs. We estimated 
the incremental cost of introducing HepB-BD vaccine 
in its monovalent form. We preferred the monovalent 
form of the vaccine in order to minimize wastage rates. 
Both recurrent and capital costs were included using an 
ingredients-based approach following WHO guidelines 
[28]. Recurrent costs included costs of vaccines, syringes, 
safety boxes, transport and maintenance, and cold chain 
storage while social mobilization and training costs were 
under capital costs (Table 3). We used the latest UNICEF 
price data for vaccines, auto-disable (AD) syringes and 
safety box adjusted for wastage rates and freight costs 
[29, 30]. Data on wastage rates and freight costs were 
retrieved from a study on economic evaluation of HBV 
vaccine in low-income countries [23]. Local data on other 
aspects of recurrent costs (transport and maintenance 
and cold chain storage) and capital costs for HepB-BD 
vaccine were not available therefore we used 2008 esti-
mates from Mozambique adjusted to the 2018 USD val-
ues [12, 31].
The medical care costs included initial assessment and 
diagnosis costs, antiviral drug costs, costs associated with 
monitoring those on treatment and not on treatment, 
and cost of managing decompensated cirrhosis (DCC) 
and hepatocellular carcinoma (HCC) (Table 3). In order 
to calculate the costs of initial assessment and diagno-
sis, we used the national guidelines on viral hepatitis to 
identify required laboratory tests and imaging modalities 
Table 2 Disability weights for different disease states used 
in the model
a Fan L, presented quality adjusted life years and we simply subtracted these 
values from one to compute disability weights
b We just took the average disability weights of the different HCC stages to 
calculate the annual HCC disability weight of 0.43
Disease state Disability weight Source
Inactive carrier 0.0 [26]
Chronic active  hepatitisa 0.01 [24]
Compensated cirrhosis 0.0 [26]
Decompensated cirrhosis 0.178 [26]
Hepatocellular carcinoma (HCC)b
 Diagnosis and primary treatment 0.288 [26]
  Metastasis 0.451 [26]
  Terminal 0.54 [26]
Table 3 Vaccination cost estimates and intervention costs in 2018 US$
a Vaccine wastage rate was assumed to be 20% and a freight rate of 6%
b Wastage and freight rates were 10% and 15%, respectively





   Vaccinea 0.25200 – [23, 29]
   Syringes and safety  boxb 0.04824 – [23, 30]
   Transport and maintenance 0.02206 – [12, 31]
   Cold chain storage 0.02213 – [12, 31]
  Capital costs
   Social mobilization 0.05276 – [12, 31]
   Training 0.34532 – [12, 31]
  Total average costs per vaccinated child 0.74251 0.50–1.00
Medical care costs (US$)
  Initial assessment and diagnosis cost 113.16 56.58–226.32 Local data
  Drug treatment 60.35 30.17–120.70 [32, 33]
  Monitoring on treatment 37.00 18.50–74.00 Local data
  Monitoring without treatment 18.50 9.25–37.00 Local data
  Average annual cost of hospital admission for decompensated cirrhosis 153.88 76.94–307.76 [34]
  Average annual cost of hospital admission for hepatocellular carcinoma 153.88 76.94–307.76 [34]
  Treatment cost of symptomatic acute infection 40.00 20.00–80.00 Assumptions
  Treatment cost of fulminant hepatitis 200.00 100.00–400.00 Assumptions
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and frequency of health care visits [11]. We collected 
laboratory cost data from local sources. The median sup-
plier price for the antiviral drug of choice (Tenofovir) was 
used to compute for annual drug cost after accounting 
for transportation costs [32, 33]. Hospital admission cost 
data for DCC and HCC were not locally available; there-
fore we used estimates from The Gambia adjusted to the 
2018 USD values [31, 34]. Costs for acute symptomatic 
conditions were based on expert estimates. All costs were 
expressed in 2018 USD. Both future costs and health 
outcomes were discounted at 3% annual rate following 
WHO recommendations [25].
Sensitivity analyses
We conducted a series of one-way sensitivity analy-
ses where we varied key input parameters one at a time 
over plausible ranges to test the robustness of our find-
ings (Table  1). Based on the findings in a one-way sen-
sitivity analysis, we proceeded and conducted two-way 
and three-way sensitivity analyses for parameters that are 
likely to change the result in a critical way. Furthermore, 
a multivariate sensitivity analysis was conducted using 
Monte Carlo simulations with n = 10,000 simulation 
runs. We varied all key parameters (vaccine effective-
ness, vaccine utilization, risk of perinatal transmission 
in HBeAg-mothers, risk of perinatal transmission in 
HBeAg + mothers, prevalence of HBV infection among 
mothers, cost of medical care, average cost per vacci-
nated child, prevalence of HBeAg in pregnant women, 
transition probability of CAH to inactive carrier state) 
simultaneously [35]. Lastly, we also ran the model with-
out discounting future health benefits or costs (one at a 
time), and without discounting both health benefits and 
costs [35].
Results
Compared to the current strategy, an additional HepB-
BD vaccine would have an incremental cost-effectiveness 
ratio of 110 USD per DALY averted (Table  4). Leav-
ing effects and both effects and costs undiscounted 
decreased the ICER to 67 USD and 49 USD per DALY 
averted, respectively.
The one-way sensitivity analyses showed that the ICERs 
would range from cost savings to maxima of USD625 per 
DALY averted. The highest ICER was observed for a 10% 
vaccine utilization, followed by a 2% risk of perinatal 
transmission when the mother was HBeAg negative and 
a 2.5% prevalence of HBV infection among mothers with 
an ICER of USD373 to 328 per DALY averted (Table 5). 
With two-way sensitivity analyses, we found that various 
combinations of vaccine effectiveness with other param-
eters would change the ICER in a substantial way as fol-
lows (Table  5). ‘’Vaccine effectiveness’ and ‘average cost 
per vaccinated child’ an ICER of 262; ‘vaccine effective-
ness’ and ‘prevalence of HBV infection among mothers’ 
an ICER of 421; ‘vaccine effectiveness’ and ‘risk of peri-
natal transmission when mother was HBeAg negative’ 
an ICER of USD475 per DALY averted; and ‘Vaccine 
effectiveness’ and ‘vaccine utilization’ would have ICER 
of USD663 per DALY averted. The three-way sensitiv-
ity analyses also showed that most parameter variations 
resulted in an ICER value of < USD485 per DALY averted 
except for some combinations of the following critical 
parameter inputs: vaccine utilization, risk of perinatal 
transmission when mother was HBeAg positive, risk of 
perinatal transmission when mother was HBeAg nega-
tive, average cost per vaccinated child and prevalence 
of HBV infection among mothers with an ICER ranging 
from USD947 to 1493 per DALY averted. On the con-
trary, a combination of the following parameters: risk of 
perinatal transmission when mother was HBeAg nega-
tive, annual cost of CAH and prevalence of HBV infec-
tion among mothers at their favorable parameter inputs 
became cost savings (hence ICER < 0). The univariate sen-
sitivity analysis demonstrated that introducing HepB-BD 
vaccine in Ethiopia is less likely to be highly cost-effective 
(at a threshold of 0.31 times the GDP per capita in Ethio-
pia, USD240 in 2018) when the vaccine utilization drops 
below 35% [36, 37].
Figure  2 shows the results of the probabilistic sen-
sitivity analysis and the uncertainty surrounding our 
cost-effectiveness estimates, with overlapping costs and 
effectiveness ranges. Regardless, the distribution pattern 
is relatively distinct with higher costs and effectiveness 
for the novel strategy (with birth dose). The willingness-
to-pay (WTP) threshold has an impact on the prob-
ability of intervention being cost-effective. At WTP 
threshold of greater than US$110 per DALYs averted, the 
four-dose regimen (with birth dose) is most likely to be 
cost-effective.
Table 4 Cost, effectiveness and incremental cost effectiveness ratio (ICER) of an additional birth dose of HB vaccine
Strategy Cost (US$) Incremental costs Effects (DALYs 
averted)
Incremental effects (DALYs 
averted)
ICER
Without birth dose 4.0243 0.001417
With birth dose 4.3538 0.3295 0.004117 0.00300 110
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For a birth cohort of 3.34 million in 2018 in Ethiopia, 
we calculated a total of 10,020 DALYs would be averted 
at a cost of nearly USD 2.5 million for HBV vaccine 
introduction (without accounting for the cost saving 
from prevention of disease states) [38].
Discussion
We conducted a cost-effectiveness analysis of HepB-BD 
vaccine in its monovalent form (compared with current 
practices) in Ethiopia and found incremental cost-effec-
tiveness ratio of USD110 per DALY averted. The ICER 









Parameters with range for sensitivity analysis ICER (US$ 
per DALY 
averted)




Vaccine utilization 66% 90 Vaccine effectiveness (60–80%) + Risk of perinatal 
transmission (HBeAg −) (2%–29%)
CS
10% 625 475
Risk of perinatal transmission (HBeAg −) 29% CS Vaccine effectiveness (60–80%) + Prevalence of HBV 
infection among mothers (2.5–10%) (10–66%)
CS
2% 373 421
Prevalence of HBV infection among mothers 10% CS Vaccine effectiveness (60%–80%) + Cost of medical 




Cost of medical care Twice the cost CS Vaccine effectiveness (60–80%) + Average cost per 
vaccinated child ($0.5–1.0) (10–66%)
13
No cost 158 262
Average cost per vaccinated child $0.5 29 Vaccine effectiveness (60–80%) + Risk of perinatal 
transmission (HBeAg +) (14–56%)
32
$1.0 195 214
Risk of prinatal transmission (HBeAg +) 56% 51 Vaccine effectiveness (60–80%) + Prevalence of 
HBeAg in pregnant women (5–25%) (10–66%)
40
14% 156 202
Prevalence of HBeAg in pregnant women 25% 59 Vaccine effectiveness (60–80%) + Transition prob. 
of CAH to inactive carrier state (30–70%) (10–66%)
35
5% 146 174
Transition prob. of CAH to inactive carrier state 30% 60
70% 124
Fig. 2 Probabilistic sensitivity analysis (n = 10,000 simulations)
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for HepB-BD is lower than the willingness-to-pay thresh-
olds suggested by Ochalek J et  al. < 0.31 times the GDP 
per capita in Ethiopia [37]. This makes investing in HepB-
BD vaccine highly cost-effective in an Ethiopian setting, 
especially in light of the cost-effectiveness of comparable 
interventions for low-income countries in sub-Saharan 
Africa [39–41]. Our cost-effectiveness findings remained 
robust to a number of sensitivity analyses (e.g. Table 5). 
Among the key parameters tested in sensitivity analyses, 
vaccine utilization was the main driver behind the cost-
effectiveness results, followed by risk of perinatal trans-
mission associated with HBeAg status, average cost per 
vaccinated child, prevalence of HBV infection among 
mothers, and treatment cost of CAH. In addition, our 
findings are comparable to those of other studies that 
studied the cost-effectiveness of birth dose of HB vaccine 
in Mozambique [12, 42].
Despite demonstrating that HepB-BD vaccine is highly 
cost-effective in an Ethiopian setting, our analysis pre-
sents a number of important limitations. First, local data 
on vaccine effectiveness, health state transition prob-
abilities, and the cost of different health states were not 
readily available which may decrease the accuracy behind 
our ICER estimates. Second, we only assessed the cost of 
tenofovir as the treatment of choice in our analysis but 
using other drugs such as entecavir might be an alter-
native cost-effective therapy [43]. Treatment of chronic 
HBV infection with entecavir consumes more resources 
as compared to treatment with tenofovir, which might 
have resulted in a less cost-effective estimate in our anal-
ysis [44]. Due to lack of community-based data on treat-
ment eligibility, we used a study conducted in a hospital 
setting, which might over represent symptomatic cases 
[20]. Third, some aspects of vaccine delivery costs (such 
as transport and maintenance, cold chain storage and 
capital costs) were based on estimates from other set-
tings that may not reflect the reality in Ethiopia. Fourth, 
another important limitation is associated with limit-
ing vaccine delivery in the medical setting. Skilled birth 
attendance rate is low and many women in Ethiopia give 
birth at home without skilled assistance, especially those 
women residing in rural areas [14]. Making HBV vaccine 
accessible to the whole population might require a com-
munity-level engagement, which might have additional 
cost implications. Cost estimates of such outreach strat-
egies were not available and not included in our model. 
Including the cost of outreach strategies in the analysis 
may result in higher ICER related to additional resource 
requirements such as transport, fuel and staff allowance 
[45]. We also assumed that additional health profession-
als would not be required to administer the birth dose of 
HB vaccine and therefore we have not included related 
costs. Even though health work force per population 
is low in Ethiopia, recent evidence suggests that there 
is underutilization of available health workforce in the 
country [46, 47]. Lastly, there may be additional impor-
tant benefits such as the equity benefits of vaccinations 
including the prevention of expensive out-of-pocket 
medical treatment for liver cancer and associated medi-
cal impoverishment into the future [48].
Successful implementation of HepB-BD vaccine 
is largely dependent on the timing of its administra-
tion. Timely administration (within 24  h of birth) of 
the vaccine may require integration with maternal and 
child health (MCH) programs rather than through the 
Expanded Program on Immunization (EPI). The sug-
gested change in the delivery of HepB-BD vaccine 
requires redesigning the MCH (immediate post-partum 
services) and EPI programs and could include other birth 
dose vaccines such as Bacille Calmette-Guérin (BCG) 
and the birth dose of oral polio vaccine (OPV-0). This 
will entail not only additional work on midwives (or 
other health personnel rendering immediate post-par-
tum services) but also logistic implications for vaccine 
storage and delivery within the maternity setting. Fur-
ther, this might require training of health personnel and 
awareness-raising campaigns nationally in Ethiopia. With 
additional efforts on social mobilization, the introduc-
tion of HepB-BD vaccine may positively contribute to the 
improvement in the coverage of skilled birth attendance 
and other birth dose vaccines in Ethiopia.
Besides, resources for health care are scarce in Ethio-
pia. The total health expenditure per capita in Ethio-
pia was about US$33 for the years 2016/2017 [49]. The 
annual budget required to introduce the birth dose of 
HBV vaccine in Ethiopia costs an additional 0.023 US$ 
per capita which is nearly 0.1% of the 2016/17 annual 
total health expenditure (3.1 billion US$) for Ethiopia. In 
the last decade, Ethiopia has enjoyed a substantial eco-
nomic development and aspires to be a middle-income 
country by 2035 [50]. Along with the economic devel-
opment, the government of Ethiopia envisions to attain 
population health status commensurate with the best 
performing middle-income countries [50]. Realization of 
such ambitious targets requires the government’s com-
mitment for more health care resource allocations.
Conclusions
Birth dose of HB vaccine is one of the most important 
preventive strategies recommended by the WHO and the 
national viral hepatitis control and prevention guidelines 
in Ethiopia. Given the formidable resource constraints in 
low-income countries such as Ethiopia, evidence on cost-
effectiveness of interventions is vital towards setting pri-
orities. Currently, the Ethiopian government is revising 
its essential health services package (EHSP). Given the 
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substantial health dividend in investing in the birth dose 
of HB vaccine in Ethiopia and the fact that it is highly 
cost-effective, it should be considered for inclusion in the 
Ethiopia’s EHSP.
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